Annexon (ANNX)
(Delayed Data from NSDQ)
$5.63 USD
+0.04 (0.72%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $5.63 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
ANNX 5.63 +0.04(0.72%)
Will ANNX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANNX
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Annexon (ANNX) This Year?
ANNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Other News for ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Annexon spikes after updating late-stage results for lead asset against GBS
Annexon Biosciences (ANNX) Gets a Buy from TD Cowen
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting